Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography

May 7, 2018International journal of cardiology

Blood levels of trimethylamine N-oxide linked to unstable artery plaque in heart disease patients

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Patients in the high TMAO group had a thinner fibrous cap thickness of 65.97 μm compared to 93.0 μm in the low TMAO group (P < 0.001).

High TMAO levels are associated with a higher frequency of microvessels in non-culprit plaques (75.6% vs. 31.1%, P < 0.001).
The incidence of thin-cap fibroatheroma (TCFA) was greater in the high TMAO group (69.2% vs. 18.4%, P < 0.001).
A negative correlation exists between TMAO levels and fibrous cap thickness (r = -0.418, P < 0.001).
TMAO levels were significantly associated with the presence of TCFA, with an odds ratio of 7.455 (P < 0.001).
A TMAO cut-off point of 118.34 μg/L predicts TCFA prevalence with a specificity of 72.6% and sensitivity of 79.5%.

AI simplified

BACKGROUND: Plaque vulnerability indicates the risk of a cardiovascular event. In the present study, we sought to analyze the relationship between trimethylamine N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, and vulnerable plaque characteristics in patients with coronary artery disease (CAD).

METHODS: One hundred eighty non-culprit plaques from 90 patients with ACS or with stable angina were assessed by optical coherence tomography (OCT). The plasma TMAO levels were measured using rapid resolution liquid chromatography quadrupole time-of-flight mass spectrometry (RRLC-QTOF/MS).

RESULTS: Patients were divided into two groups (high TMAO group and low TMAO group) according to the median plasma TMAO level (114.73 μg/L). The non-culprit plaques in the high TMAO group exhibited a thinner fibrous cap thickness (FCT) (65.97 ± 25.89 vs. 93.0 ± 28.28 μm, P < 0.001), higher frequency of microvessels (75.6% vs. 31.1%, P < 0.001, per-patient) and increased incidence of thin-cap fibroatheroma (TCFA) (69.2% vs. 18.4%, P < 0.001, per-patient) compared with the low TMAO group. Moreover, the level of TMAO was negatively associated with FCT (r = -0.418, P < 0.001). Furthermore, multivariate regression analysis results showed that TMAO (OR: 7.455, 95% CI: 2.753-20.189, P < 0.001) had a significant association with TCFA, with a cut-off point of 118.34 μg/L, specificity of 72.6% and sensitivity of 79.5% in predicting the prevalence of TCFA.

CONCLUSIONS: In conclusion, these findings suggest that the level of TMAO is significantly correlated with the incidence of TCFA. New biomarkers acquired through non-invasive means, such as TMAO, offer the potential to improve risk stratification and clinical management in patients with CAD.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief